176 related articles for article (PubMed ID: 15621812)
1. In vitro drug resistance to imatinib and mutation of ABL gene in childhood Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
Kawaguchi H; Taketani T; Hongo T; Park MJ; Koh K; Ida K; Kobayashi M; Takita J; Taki T; Yoshino H; Bessho F; Hayashi Y
Leuk Lymphoma; 2005 Feb; 46(2):273-6. PubMed ID: 15621812
[TBL] [Abstract][Full Text] [Related]
2. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
[TBL] [Abstract][Full Text] [Related]
3. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.
Hofmann WK; Komor M; Wassmann B; Jones LC; Gschaidmeier H; Hoelzer D; Koeffler HP; Ottmann OG
Blood; 2003 Jul; 102(2):659-61. PubMed ID: 12663457
[TBL] [Abstract][Full Text] [Related]
4. Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation.
Kancha RK; von Bubnoff N; Miething C; Peschel C; Götze KS; Duyster J
Haematologica; 2008 Nov; 93(11):1718-22. PubMed ID: 18728023
[TBL] [Abstract][Full Text] [Related]
5. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
Redaelli S; Piazza R; Rostagno R; Magistroni V; Perini P; Marega M; Gambacorti-Passerini C; Boschelli F
J Clin Oncol; 2009 Jan; 27(3):469-71. PubMed ID: 19075254
[No Abstract] [Full Text] [Related]
6. [The different characteristics of ABL kinase domain mutation in the Chinese Han nationality imatinib resistant Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia].
Shen HJ; He J; Qiu QC; Cen JN; Pan JL; Yao L; Ding ZX; Chen Y; Chen ZX
Zhonghua Xue Ye Xue Za Zhi; 2013 Jan; 34(1):21-5. PubMed ID: 23597459
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
Pfeifer H; Lange T; Wystub S; Wassmann B; Maier J; Binckebanck A; Giagounidis A; Stelljes M; Schmalzing M; Dührsen U; Wunderle L; Serve H; Brück P; Schmidt A; Hoelzer D; Ottmann OG
Leukemia; 2012 Jul; 26(7):1475-81. PubMed ID: 22230800
[TBL] [Abstract][Full Text] [Related]
8. Existence of leukemic clones resistant to both imatinib mesylate and rituximab before drug therapies in a patient with Philadelphia chromosome-positive acute lymphocytic leukemia.
Hato T; Yamanouchi J; Tamura T; Hojo N; Niiya Y; Kohno M; Bando S; Yakushijin Y; Takada K; Sakai I; Yasukawa M; Fujita S
Int J Hematol; 2004 Jul; 80(1):62-6. PubMed ID: 15293570
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
10. Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.
Hawkins LM; Jayanthan AA; Narendran A
Pediatr Res; 2005 Mar; 57(3):430-7. PubMed ID: 15659698
[TBL] [Abstract][Full Text] [Related]
11. Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.
Grammatico S; Elia L; Peluso AL; Pedace L; Matarazzo M; Vitale A; Rago A; Pane F; Foà R; Cimino G
Leuk Res; 2009 Jul; 33(7):e73-4. PubMed ID: 19108887
[No Abstract] [Full Text] [Related]
12. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
Jones D; Thomas D; Yin CC; O'Brien S; Cortes JE; Jabbour E; Breeden M; Giles FJ; Zhao W; Kantarjian HM
Cancer; 2008 Sep; 113(5):985-94. PubMed ID: 18615627
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Thomas X; Dombret H
Leuk Lymphoma; 2008 Jul; 49(7):1246-54. PubMed ID: 18452076
[TBL] [Abstract][Full Text] [Related]
14. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
[TBL] [Abstract][Full Text] [Related]
15. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Pfeifer H; Wassmann B; Pavlova A; Wunderle L; Oldenburg J; Binckebanck A; Lange T; Hochhaus A; Wystub S; Brück P; Hoelzer D; Ottmann OG
Blood; 2007 Jul; 110(2):727-34. PubMed ID: 17405907
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.
Ottmann O; Dombret H; Martinelli G; Simonsson B; Guilhot F; Larson RA; Rege-Cambrin G; Radich J; Hochhaus A; Apanovitch AM; Gollerkeri A; Coutre S
Blood; 2007 Oct; 110(7):2309-15. PubMed ID: 17496201
[TBL] [Abstract][Full Text] [Related]
17. Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges.
Thomas DA
Hematology Am Soc Hematol Educ Program; 2007; ():435-43. PubMed ID: 18024662
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ottmann OG; Wassmann B
Hematology Am Soc Hematol Educ Program; 2005; ():118-22. PubMed ID: 16304368
[TBL] [Abstract][Full Text] [Related]
19. Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study.
Chang BH; Willis SG; Stork L; Hunger SP; Carroll WL; Camitta BM; Winick NJ; Druker BJ; Schultz KR
Br J Haematol; 2012 May; 157(4):507-10. PubMed ID: 22299775
[No Abstract] [Full Text] [Related]
20. Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia.
Hofmann WK; Komor M; Hoelzer D; Ottmann OG
Leuk Lymphoma; 2004 Apr; 45(4):655-60. PubMed ID: 15160936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
